Innovative Pharmaceutical Biotech Limited provided group earnings guidance for the six months ending 30 September 2022. For the period, the company expects unaudited management accounts, the Group is expected to record a loss attributed to equity shareholders of the Company for the six months ended 30 September 2022 in the range between HKD 110 million and HKD 130 million, compared to the profit of approximately HKD 121.1 million for the six months ended 30 September 2021 (the "Corresponding Period"), which was mainly attributable to the non-cash item resulted from the completion of the modification of convertible bond in the Corresponding Period. The difference of the carrying value of the convertible bond and fair value of the liability component of the convertible bond at the completion amounted to approximately HKD 250.7 million was credited to the income statement of the Corresponding Period.